OOIR: Observatory of International Research

Papers

(The median citation count of Translational Neurodegeneration is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Retraction Note: Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson’s disease	316
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	283
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	179
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	168
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	139
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	108
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	105
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	88
Impaired dynamic interaction of axonal endoplasmic reticulum and ribosomes contributes to defective stimulus–response in spinal muscular atrophy	86
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	81
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	80
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	80
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	79
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	77
Role of dopamine in the pathophysiology of Parkinson’s disease	70
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	69
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	65
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	64
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	63
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	63
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	61
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	58
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	56
NMDAR-dependent somatic potentiation of synaptic inputs is correlated with β amyloid-mediated neuronal hyperactivity	56
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	54

Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta	52
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	52
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	52
Inflammasomes in neurodegenerative diseases	50
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	47
Nose-to-brain drug delivery: from bench to bedside	46
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	45
Peripheral proteinopathy in neurodegenerative diseases	45
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	45
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	43
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	43
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	42
Multidimensional biomarkers for multiple system atrophy: an update and future directions	41
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	41
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	41
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	40
Mitochondrial links between brain aging and Alzheimer’s disease	40
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	39
Perivascular spaces relate to the course and cognition of Huntington’s disease	39
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	38
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	38
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis	38
Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment	38
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	36
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	35
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	34
Genetic spectrum and clinical features in a cohort of Chinese patients with autosomal recessive cerebellar ataxias	34
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	34
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	33
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	32
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock	32
Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity	31
Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson’s disease model	31
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	31
Effects of transcranial ultrasound stimulation pulsed at 40 Hz on Aβ plaques and brain rhythms in 5×FAD mice	31
Plasma proteomic signatures as predictors of dementia risk in individuals with sleep apnea: a cohort study	30
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use	29
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	29
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases	29
Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease	29
Alterations in sleep-activity cycles and clock gene expression across the synucleinopathy spectrum	27
Biases in α-synuclein immuno-quantitation: a core problem for basic and ancillary studies of Parkinson’s disease and multiple system atrophy	27
Nootropic foods in neurodegenerative diseases: mechanisms, challenges, and future	27
Retrotransposon: an insight into neurological disorders from perspectives of neurodevelopment and aging	27
Stress granules: emerging players in neurodegenerative diseases	27
Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics	26
Linking APOE4/4 genotype to microglial lipid droplets and neurotoxicity in Alzheimer’s disease	26
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease	26
Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine	25
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials	25

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model	24
The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population	24
CSF biomarkers of reactive glial cells are associated with blood–brain barrier leakage and white matter lesions	23
Correction: CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation	23
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration	23
Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation	22
Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges	22
Myelin repair in Alzheimer’s disease: a review of biological pathways and potential therapeutics	22
TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut	22
Increased cysteinyl-tRNA synthetase drives neuroinflammation in Alzheimer’s disease	22
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease	21
Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in Drosophila	21
GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model	19
Endosomal traffic disorders: a driving force behind neurodegenerative diseases	19
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases	19
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	19
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease	19
TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease	19
Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise	18
Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies	18
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease	18
Glutathione oxidation in cerebrospinal fluid as a biomarker of oxidative stress in amyotrophic lateral sclerosis	17
Alleviating the unwanted effects of oxidative stress on Aβ clearance: a review of related concepts and strategies for the development of computational modelling	17
APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease	17
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases	16
Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification	16
N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson’s disease	16
Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson’s disease and multiple system atrophy	16
Research progress on the role of extracellular vesicles in neurodegenerative diseases	16
Genetic heterogeneity on sleep disorders in Parkinson’s disease: a systematic review and meta-analysis	16
N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology	16
CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy	16
RNA targets of TDP-43: Which one is more important in neurodegeneration?	15
Long-term exercise enhances meningeal lymphatic vessel plasticity and drainage in a mouse model of Alzheimer's disease	15
The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases	15
Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer’s Disease	15
Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases	14
Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease	14
α-Synuclein arginylation in the human brain	14
Putative novel CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort	14
Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis	14
Optogenetic induction of TDP-43 aggregation impairs neuronal integrity and behavior in Caenorhabditis elegans	14
Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	14
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease	14
Translational Neurodegeneration in the era of fast growing international brain research	14
Multi-mechanical waves against Alzheimer’s disease pathology: a systematic review	13
Neddylation-dependent protein degradation is a nexus between synaptic insulin resistance, neuroinflammation and Alzheimer’s disease	13
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction	13
Chronic subthalamic nucleus deep brain stimulation reduces pathological TrkB aggregates in a Parkinson’s disease rat model	13
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms	13
Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system	13
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease	13